GlassScriptPhysician profile
Steven L Martin
NPI 1023107067
$55,263.53
in general payments reported to CMS, 2019-2025
39 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $1,733 · 2021: $3,364 · 2022: $7,570 · 2023: $14K · 2024: $2,757 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $4,333 · Travel and Lodging: $2,688 · Consulting Fee: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,500.00 |
| Food and Beverage | $4,333.49 |
| Travel and Lodging | $2,687.53 |
| Consulting Fee | $2,250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $31,576.50 | 2019-2025 | Watchman Access System, Emblem Mri S-Icd, Lux-Dx Insertable Cardiac Monitor |
| Edwards Lifesciences Corporation | $18,614.02 | 2019-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Abbott Laboratories | $2,185.17 | 2020-2025 | Triclip, Navitor, Esprit |
| Novartis Pharmaceuticals Corporation | $525.06 | 2021-2025 | |
| Pfizer INC. | $356.94 | 2019-2025 | |
| Amgen INC. | $312.85 | 2020-2024 | Repatha |
| Medtronic, INC. | $234.61 | 2021-2025 | Venaseal, Corevalve Evolut R, Symplicity G3 |
| Merck Sharp & Dohme LLC | $164.25 | 2021-2025 | Verquvo, Bridion |
| E.R. Squibb & Sons, L.L.C. | $160.85 | 2019-2025 | Camzyos |
| Impulse Dynamics (USA) INC. | $138.97 | 2022-2025 | Optimizer, Optimizer |
| Itamar Medical INC | $103.65 | 2022-2023 | Watchpatone |
| Janssen Pharmaceuticals, INC | $90.31 | 2019-2024 | Xarelto |
| Abiomed | $85.33 | 2021-2024 | Impella |
| Sunovion Pharmaceuticals INC. | $65.69 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.27 | 2019-2024 | Jardiance |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $52.67 | 2021-2024 | Farxiga, Brilinta |
| Esperion Therapeutics, INC. | $52.20 | 2020-2022 | |
| Chiesi USA, INC. | $50.66 | 2019-2024 | Kengreal |
| Philips North America LLC | $50.32 | 2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.05 | 2023-2024 | Lifevest |
| Shockwave Medical, INC | $36.81 | 2025 | |
| Baxter Healthcare | $31.79 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Novo Nordisk INC | $31.36 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Amarin Pharma, INC. | $30.48 | 2019 | |
| Bridgebio Pharma, INC. | $28.72 | 2025 | Attruby |
| Biotronik INC. | $21.20 | 2021 | |
| Angiodynamics, INC. | $19.31 | 2022 | |
| Heartflow, INC. | $18.48 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.92 | 2024 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $16.66 | 2019 | |
| Bard Peripheral Vascular, INC. | $16.06 | 2025 | |
| Inspire Medical Systems, INC. | $15.78 | 2024 | Inspire |
| Lexicon Pharmaceuticals, INC. | $13.51 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals, LTD. | $13.38 | 2023 | Arcalyst |
| Ge Healthcare | $13.28 | 2021 | |
| Gilead Sciences, INC. | $12.42 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.